Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age
详细信息 查看全文
- 作者：Suguru Mizuno (1)
Yousuke Nakai (1)
Hiroyuki Isayama (1)
Ayako Yanai (2)
Naminatsu Takahara (1)
Koji Miyabayashi (1)
Keisuke Yamamoto (1)
Kazumichi Kawakubo (1)
Dai Mohri (1)
Hirofumi Kogure (1)
Takashi Sasaki (1)
Natsuyo Yamamoto (1)
Naoki Sasahira (1)
Kenji Hirano (1)
Takeshi Tsujino (1)
Hideaki Ijichi (1)
Keisuke Tateishi (1)
Masao Akanuma (2)
Minoru Tada (1)
Kazuhiko Koike (1) - 关键词：Pancreatic cancer ; Diabetes ; Risk factor
- 刊名：Journal of Gastroenterology
- 出版年：2013
- 出版时间：February 2013
- 年：2013
- 卷：48
- 期：2
- 页码：238-246
- 全文大小：385KB
- 参考文献：1. Ministry of Health, Labour and Welfare. Vital Statistics Japan. 2008.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-6. CrossRef
3. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464-4. CrossRef
4. Huxley R, Ansary-Moghaddam A. Berrington de Gonzalez A, Barzi F and Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-3. CrossRef
5. Lin Y, Kikuchi S, Tamakoshi A, Yagyu K, Obata Y, Inaba Y, et al. Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer. 2007;120:2665-1. CrossRef
6. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007;120:1993-. CrossRef
7. Tada M, Kawabe T, Arizumi M, Togawa O, Matsubara S, Yamamoto N, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265-0. CrossRef
8. Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, Takakura R, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008;57:1561-. CrossRef
9. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-1. CrossRef
10. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766-1 (quiz 665).
11. Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946-4. CrossRef
12. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-01. CrossRef
13. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981-. CrossRef
14. Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009;104:2318-5. CrossRef
15. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605-. CrossRef
16. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194-02. CrossRef
17. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract. 2002;55:65-5. CrossRef
18. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504-1.
19. Gupta S, Vittinghoff E, Bertenthal D, Corley D, Shen H, Walter LC, et al. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4:1366-2 (quiz 1301).
20. Permert J, Larsson J, Westermark GT, Herrington MK, Christmanson L, Pour PM, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med. 1994;330:313-. CrossRef
21. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, et al. Pancreatic cancer-derived S-100A8?N-terminal peptide: a diabetes cause? Clin Chim Acta. 2006;372:120-. CrossRef
22. Pfeffer F, Koczan D, Adam U, Benz S, von Dobschuetz E, Prall F, et al. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas. 2004;29:284-0. CrossRef
23. Wang F, Larsson J, Adrian TE, Gasslander T, Permert J. In vitro influences between pancreatic adenocarcinoma cells and pancreatic islets. J Surg Res. 1998;79:13-. CrossRef
24. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482-. CrossRef
25. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20. CrossRef
26. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-7. CrossRef
27. Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34:923-. CrossRef
28. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut. 2004;53:1688-7. CrossRef
29. Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 2001;94:370-. CrossRef
30. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40:768-2. CrossRef
31. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182:897-03.
32. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007;102:2157-3. CrossRef
33. Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas. 1994;9:703-. CrossRef
34. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19- as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182-. CrossRef
35. Zubarik R, Gordon SR, Lidofsky SD, Anderson SR, Pipas JM, Badger G, et al. Screening for pancreatic cancer in a high-risk population with serum CA 19- and targeted EUS: a feasibility study. Gastrointest Endosc. 2011;74:87-5. CrossRef
36. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331:81-. CrossRef - 作者单位：Suguru Mizuno (1)
Yousuke Nakai (1)
Hiroyuki Isayama (1)
Ayako Yanai (2)
Naminatsu Takahara (1)
Koji Miyabayashi (1)
Keisuke Yamamoto (1)
Kazumichi Kawakubo (1)
Dai Mohri (1)
Hirofumi Kogure (1)
Takashi Sasaki (1)
Natsuyo Yamamoto (1)
Naoki Sasahira (1)
Kenji Hirano (1)
Takeshi Tsujino (1)
Hideaki Ijichi (1)
Keisuke Tateishi (1)
Masao Akanuma (2)
Minoru Tada (1)
Kazuhiko Koike (1)
1. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
2. Department of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Chiyoda-ku, Tokyo, Japan - ISSN：1435-5922
文摘
Background Diabetes mellitus (DM) has long been recognized as a risk factor for pancreatic cancer (PaC) and recently has attracted attention as a manifestation of PaC. Diabetes is expected to be a clue for the early detection of PaC; however, no effective screening strategy has been established. Methods Forty diabetic patients with PaC were identified and compared with 120 diabetic patients without any malignancies. We analyzed risk factors for and early signs of PaC, focusing on the DM-onset age. Results As there were peaks at 40-5 years and 60-5 years in the distribution of DM-onset age, we analyzed the clinical characteristics of and risk factors for PaC according to DM-onset age: i.e., early-onset (<55?years) and late-onset (?5?years). PaC was diagnosed within 2?years of DM onset (new-onset) in 0?% of the patients with early-onset DM, and in 33?% of those with late-onset DM. The mean duration of DM in patients with early-onset DM with PaC was longer than that in the late-onset patients (26 vs. 9?years; P?<?0.01). A family history of DM (odds ratio [OR] 3.60) and use of insulin (OR 3.52) were significant risk factors in patients with early-onset DM, while the onset age of DM (OR 1.12) and multiple diabetic patients in the family (OR 6.13) were risk factors in those with late-onset DM. Body weight loss and exacerbation of DM were seen 12?months prior to PaC diagnosis in both groups. Conclusions Our study revealed specific risk factors for and similar early signs of PaC in early-onset and late-onset DM. Thus, we could develop a screening strategy, combining these risk factors specific for DM-onset age with early signs of disease.